Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST

BACKGROUND: Immunotherapy represents a new therapeutic approach in non-small cell lung carcinoma (NSCLC) with the potential for prolonged benefits. Because of the systemic nature and heterogeneity of tumoral diseases, as well as the immune restoration process induced by immunotherapy, the assessment...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldfarb, Lucas, Duchemann, Boris, Chouahnia, Kader, Zelek, Laurent, Soussan, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890907/
https://www.ncbi.nlm.nih.gov/pubmed/30694399
http://dx.doi.org/10.1186/s13550-019-0473-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890907/
https://www.ncbi.nlm.nih.gov/pubmed/30694399
http://dx.doi.org/10.1186/s13550-019-0473-1

Ejemplares similares